Tianjin Holdings Subsidiary Secures New Wealth Product
Company Announcements

Tianjin Holdings Subsidiary Secures New Wealth Product

Tianjin Development Holdings (DE:TJN) has released an update.

Tianjin Development Holdings’ subsidiary, Lisheng Pharmaceutical, has entered into a new wealth management agreement with CBHB, subscribing to a structured deposit of RMB210 million. The deposit, with a term from September 30, 2024, to February 7, 2025, offers an annualized return rate between 1.5% and 2.5%. This transaction is classified as discloseable under the Listing Rules, with all applicable percentage ratios below 25%.

For further insights into DE:TJN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskTianjin Development Reports Profit Decline at Lisheng Pharma
TipRanks HongKong Auto-Generated NewsdeskTianjin Development Strikes Key Deals with TEDA Holding
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App